Articles

One of the current challenges in the field of CAR-T cell therapy is the lack of a simple assay to easily detect and quantify CAR expression following T cell transduction. Read this article to learn about the advantages of using R&D Systems™ fluorescent-labeled proteins to directly stain and detect CAR+ cells by flow cytometry.

From off-the-shelf proteins to custom protein products, our protein leadership team provides high-grade project-specific solutions.  Read how R&D Systems’ protein development group specializes in making the world’s most difficult proteins for research and therapeutics.

Anthony Person is a protein expert whose roots were laid in academia and continued to grow in the biopharmaceutical industry. As the Senior Director of the Protein Business Unit, Anthony drives forward the growing protein division at Bio-Techne. In a Q&A format, Anthony gives us his perspective on all things proteins – from his day-to-day and the proteins that support cell and gene therapy, to a brand-new, world-class protein manufacturing facility.

To facilitate communication and collaboration across the cell and gene therapy (CGT) field, Bio-Techne hosted the first CPD-certified Cell & Gene Therapy Symposium on the 7th November 2019 at the QEII Centre in central London. With an overarching topic of ‘Meeting the Challenges of Scale: Designing the Cell & Gene Therapies of the Future’ the one-day forum aimed to provide a much-needed platform to discuss the key topics and challenges faced and important solutions for these—as the manufacturing of advanced therapy medicinal products (ATMPs) at scale becomes a reality...

When assessing phosphorylation, the method of choice may vary depending on many factors including the specific question being asked and availability of specialized equipment or reagents. This review provides a brief description of several methodologies currently used and addresses some of the benefits and drawbacks associated with each.

Growth factors, through receptor tyrosine kinases, recruit a large network of signaling proteins to execute their cellular programs. These examples in this review highlight the continuing need for new drugs and targets and inhibition of the ERK pathway remains promising for cancer therapies.

This review goes over the examples of iPS cells differentiating into various somatic cell types pave the way for generating patient-specific pluripotent cells that could be used for research and therapy. Disease research, drug development, and patient therapy will be greatly enhanced by the ability to recapitulate normal and pathologic tissue differentiation and formation in vitro, which iPS cells provide more readily than ES cells.

A group of intracellular proteases called caspases are responsible for the deliberate disassembly of the cell into apoptotic bodies during apoptosis.

Traditionally, macrophages have been described as antigen-presenting phagocytes that secrete pro-inflammatory and antimicrobial mediators. Mounting evidence, however, describes a more complex model involving multiple macrophage phenotypes carrying out differential functions and eliciting divergent effects on surrounding cells and tissues.